| Laura Elizabeth Morris, MD | |
|
110 N Hospital Dr, Fulton, MO 65251-2511 | |
| (573) 642-5911 | |
| (573) 642-3015 |
| Full Name | Laura Elizabeth Morris |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 110 N Hospital Dr, Fulton, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1588862841 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2010005858 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Missouri Health Care | Columbia, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Curators Of The University Of Missouri | 4486759560 | 959 |
News Archive
Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.
Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company's first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
BioNeutral Group Inc., a specialty chemical technology-based life science company, today announced financial results for the third quarter and nine-month period ended July 31, 2010.
It's a decision being made thousands of times over inside hospitals all around the country: is it time to place a patient struggling to breathe on a ventilator?
› Verified 2 days ago
| Entity Name | The Curators Of The University Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235126921 PECOS PAC ID: 4486759560 Enrollment ID: O20070418000290 |
News Archive
Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.
Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company's first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
BioNeutral Group Inc., a specialty chemical technology-based life science company, today announced financial results for the third quarter and nine-month period ended July 31, 2010.
It's a decision being made thousands of times over inside hospitals all around the country: is it time to place a patient struggling to breathe on a ventilator?
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Laura Elizabeth Morris, MD Po Box 843966, Kansas City, MO 64184-3966 Ph: (573) 884-3300 | Laura Elizabeth Morris, MD 110 N Hospital Dr, Fulton, MO 65251-2511 Ph: (573) 642-5911 |
News Archive
Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled "Prone to Error: Earliest Steps to Find Cancer" highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics. The story focused on widespread problems associated with incorrect diagnosis of breast cancer, and cited one study in which 90,000 women either did not have the disease or their pathologist made an error that resulted in incorrect treatment.
Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company's first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.
BioNeutral Group Inc., a specialty chemical technology-based life science company, today announced financial results for the third quarter and nine-month period ended July 31, 2010.
It's a decision being made thousands of times over inside hospitals all around the country: is it time to place a patient struggling to breathe on a ventilator?
› Verified 2 days ago
Sophi Thurman, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 | |
Heather L Pierce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 | |
Dr. William P Cravens, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 850 West Hospital Drive, Suite A, Fulton, MO 65251 Phone: 573-592-0337 Fax: 573-592-0711 | |
Brice P Windsor, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2613 Fairway Dr, Fulton, MO 65251 Phone: 573-642-1990 Fax: 573-642-5089 | |
Dr. Rezwan Islam, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 850 N Hospital Dr, Ste D, Fulton, MO 65251 Phone: 573-642-5338 Fax: 573-642-9224 | |
James J Stevermer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 | |
Mark Cameron Dodds, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 110 N Hospital Dr, Fulton, MO 65251 Phone: 573-642-5911 Fax: 573-642-3015 |